Immunogenicity of the UK group B meningococcal vaccine (4CMenB) schedule against groups B and C meningococcal strains (Sched3): outcomes of a multicentre, open-label, randomised controlled trial (Lancet Infectious Diseases, 2021)

(untitled) - Davis, K; Valente Pinto, M; Andrews, NJ; Goldblatt, D; Borrow, R; Findlow, H; Southern, J; Partington, J; Plested, E; Patel, S; Holland, A; Matheson, M; et al.